The TRC4: How the University of Texas is Innovating Trauma Care Through System-wide Collaboration
|
The Trauma Research and Combat Casualty Care Collaborative (TRC4), led by The University of Texas System (UT System), is driving transformative change with grants to advance trauma research, product development, and preventative measures across UT institutions. These initiatives, ranging from enhancing burn tissue viability assessment to harnessing AI for care delivery efficiency, underscore TRC4's commitment to improving trauma care outcomes through interdisciplinary collaboration and innovative solutions.
|
Celestial Event Overshadowed by Immigration Masterclass
for Visa-Seeking Life Science Talent
|
The growth of life sciences, research, pharmaceuticals, and therapeutic drug development has dramatically increased the need for retaining top tier international talent at regional, state, and national levels. One of the most diverse areas of the country, North Texas is a home to thousands of foreign nationals living, working, or studying with one of several international visas.
Recognizing this development and the needs of this vulnerable international talent pool; BioNTX partnered with sector leaders Fragomen and David/Yost Morgan Stanley to host a workshop centered on navigating various visa pathways and resources for individuals seeking to make their stay more permanent. Attendees, which included researchers, students, professionals, and founders where able to engage with experts and connect with resources for success. BioNTX and its partner members are committed to offering guidance and resources to the community of academic researchers, students, and professionals that innovate solutions to address the world's most challenging problems.
|
Navigating Clinical Trials & Maximizing Innovation
in Drug Therapy Development
|
Join BioNTX and Caidya for an engaging, in-depth review of the clinical trial landscape.
Experts will discuss effective strategies to streamline early phase trial design and address CMC challenges head-on. Founders and innovators, come learn how to better optimize efficiency while fostering innovation in your pipelines.
|
Monthly Happy Hour to Follow!
|
Today's Ideas, Tomorrow's Standards
|
Pegasus Park serves as the nucleus of North Texas' thriving life science ecosystem. The upcoming addition of Bridge Labs Pegasus Park marks a milestone, offering 135,000 square feet of meticulously designed research and development space—the first of its kind in the region. Adjacent to the existing 37,000-square-foot BioLabs facility, this expansion signifies a significant leap forward, providing non-incubator space with unparalleled specifications including enhanced power, HVAC, and gas service, alongside cutting-edge laboratory amenities and shared spaces.
|
Kellogg Business School Comes to Pegasus Park
with Future of Healthcare Summit
|
Join BioNTX, the Northwestern University Kellogg School of Management, and the North Texas Life Science Community in forging new economic strategies in healthcare innovation at the intersection of health tech, science, and equity.
|
Texas A&M AgriLife Develops
Decision Support Program for Sustainable Farming
|
Dr. Raghavan Srinivasan Ph.D., at Texas A&M AgriLife Research has created an Integrated Decision Support System (IDSS) tailored for agricultural producers. The program model is a crucial step towards enhancing efficiency and sustainability in farming practices. Substantial grant funding from the National Institute of Food and Agriculture underscores the importance of this project and its potential impact on the agricultural community.
By integrating advanced predictive modeling techniques with diverse data sources, including weather patterns, market prices, production costs, and water conservation practices, the IDSS can provide farmers with valuable insights and potentially save billions of dollars.
|
UNT Researcher Explores Women's Health Futures
Through Environmental & Genetic Factors
|
Dr. Julia Heck, the Associate Dean for Research at the University of North Texas, is deeply committed to advancing women's health. An expert in epidemiology, the Columbia University Ph.D. now leads groundbreaking research on maternal and child health, focusing on environmental toxins and genetic conditions.
Heck's work, spanning PFAS exposure and eye cancer risk in children to AATD and pregnancy complications, aims to empower individuals to safeguard women's health. Through rigorous research and advocacy, Heck expands scientific knowledge and encourages proactive measures in women's health during pregnancy and beyond.
|
New DEC Network Accelerator at RedBird
Brings Innovation & Creative Space to South Dallas
|
Southern Dallas County entered a new chapter of creative collaboration as the DEC Network unveiled their newly remodeled innovation hub in the Shops at RedBird. The former RedBird mall is already home to new satellite campuses for Parkland Hospital, UT Southwestern Medical Center, Dallas College, and the DEC Network; and will now offer 20,000 square feet of office space to support entrepreneurs entering the North Texas ecosystem.
|
Alpha Cognition Reaches Strategic FDA Milestones
for Alzheimer's Therapy Candidate
|
Alpha Cognition has achieved significant milestones, including FDA acceptance of their NDA for ALPHA-1062 and the submission of a new patent.
The company has announced the securement $8.45 million in financing and plan to strategically launch ALPHA-1062 in the LTC market segment, followed by expansion into Neurology. This new development of a sublingual formulation reflects Alpha Cognition's commitment to innovative Alzheimer's therapies.
Congratulations Alpha Cognition on a Huge Milestone in North Texas!
|
FDA Approves Johnson & Johnson's CARVYKTI®
as Targeted Therapy for Multiple Myeloma
|
Johnson & Johnson received FDA approval for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) to treat relapsed or refractory multiple myeloma in adults who've had prior therapy, including lenalidomide. CARVYKTI® is the first BCMA-targeted therapy approved for multiple myeloma as early as first relapse. The approval is based on positive Phase 3 CARTITUDE-4 study results, showing a 59% reduction in disease progression or death risk compared to standard therapies. Dr. Binod Dhakal praised CARVYKTI's efficacy and the potential for treatment-free periods, offering hope for managing this challenging disease.
|
Lantern Pharma is Revolutionizing Oncology
and Changing Traditional Developmental Timelines
|
Lantern Pharma is rapidly advancing oncology treatment with its streamlined approach, utilizing AI and big data to accelerate drug development. Led by CEO Panna Sharma, the company has three drugs in trial stages and recently obtained FDA orphan drug designation for LP-284, a promising treatment for a rare form of non-Hodgkin’s lymphoma, with minimal investment costs. Their innovative strategy holds the potential to deliver impactful treatments swiftly and affordably, challenging traditional norms in the industry. While the traditional developmental timeline for a drug therapy or candidate can be upwards of 12 years, Lantern's AI platform technology has already produced several therapy candidates currently in trials in just a few years.
|
OncoNano Report Findings Highlight Ideal Scenario
for Breakthrough Nanoparticles
|
At the recent 2024 AACR Annual Meeting, OncoNano Medicine unveiled groundbreaking research on muONM-412, a novel encapsulated murine interleukin-12 fusion protein (IL-12Fc) housed within the company's ON-BOARD™ nanoparticles. The notice highlights the promising preclinical efficacy and safety profile of muONM-412, tackling the persistent challenges linked with IL-12 therapy. By leveraging proprietary ON-BOARD™ nanoparticle technology, OncoNano enhances the tolerability of IL-12Fc while preserving its potent antitumor efficacy.
|
Deloitte Invests $2 B in IndustryAdvantage™
to Drive Digital Transformation Across Industry
|
Deloitte has announced a strategic $2 billion investment in IndustryAdvantage™, aimed at empowering businesses across sectors to innovate and thrive in today's rapidly evolving technological landscape. This initiative focuses on leveraging domain expertise, modern engineering principles, artificial intelligence (AI), and cybersecurity to accelerate the development of industry-specific solutions.
|
RSM Named in Fortune's 100 Best Companies to Work
|
RSM US, a leading provider of assurance, tax, and consulting services for the middle market, has once again been honored as one of the Fortune 100 Best Companies to Work For® in 2024 by Great Place To Work® and Fortune magazine. This marks RSM's fourth inclusion in this prestigious list, securing the 44th position this year.
The recognition highlights the firm's ongoing commitment to nurturing an exceptional workplace culture and providing a positive experience for its employees. The evaluation process involved gathering confidential feedback from employees and analyzing HR data to assess various aspects of workplace satisfaction and performance.
|
Design Files: A Look at Perkins & Will's Vision for
Sustainable Urban Agriculture Via Scientific Innovation
|
Perkins&Will has received funding from the Government of Canada and the Agricultural Clean Technology Program Research and Innovation Stream. Totaling CAD $429,000 over three years, this funding will support the project "Resource Circularity: Waste-to-Resource Closed Loop Ecosystems." Led by senior researcher Mohamed Imam, Ph.D., Perkins&Will will collaborate with industry partners from the University of British Columbia, the City of Vancouver, and local urban farming experts to advance research on urban agriculture and resource circularity practices. With a combined in-kind contribution of $200,000 from partners, the project aims to reduce environmental impact in agriculture, contributing to Canada's sustainable future while addressing evolving city policies on food security and resilience.
|
UTA Professor Awarded Silver Jubilee Chemistry Medal
for Analytical & Separation Science
|
Dr. Kevin Schug, the Shimadzu Distinguished Professor of Analytical Chemistry at the University of Texas at Arlington, has received the prestigious 2024 Silver Jubilee Medal from the Chromatography Society for his significant contributions to separation science. Recognized for his work in gas and liquid separations, Schug has also played a pivotal role in forming collaborative partnerships with industry leaders. His groundbreaking research, particularly in vacuum ultraviolet (VUV) detection for gas chromatography, has greatly advanced analytical methodologies across various sectors, earning him widespread acclaim in the scientific community.
|
UT Dallas Sciences Building Dedication Ceremony
a Reflection of Commitment to Innovation & Sustainability
|
(from left to right) UTD mascot Temoc; Dr. Inga Musselman, University provost; mathematics senior Alison Spadaro; UT System Regent Christina Melton Crain; Dr. David Hyndman, dean of the School of Natural Sciences and Mathematics; President Richard Benson; Dr. Calvin Jamison, vice president for facilities and economic development; Richardson Mayor Pro Tem Arefin Shamsul; and UTD cheerleader Olivia Martinez
|
The University of Texas at Dallas celebrates the dedication of the Sciences Building and enhanced campus gateway. The building- which has been recognized for sustainability, accommodates the Department of Physics, classrooms, offices, teaching and research labs, and activities of the William B. Hanson Center for Space Sciences.
Achieving LEED Gold status for sustainable design, the building was designed to utilize regionally sourced materials and technologies that significantly reduce water consumption. Energy-efficient equipment and lighting reduce energy use, and about 75% of demolition and construction waste was diverted from landfills through recycling. Nearly a quarter of the building materials are made of recycled content, including concrete, steel, framing, drywall and flooring.
|
UTSW Researchers Discover Novel Immune Pathway
with Potential Broad Spectrum Application
|
(from left to right) Don Gammon, PhD and Emily Rex
|
Dr. Don Gammon and Emily Rex led a team at UT Southwestern Medical Center in identifying an antiviral immune pathway with broad-spectrum efficacy against various viruses, featured in Nature Microbiology. Their research revealed the A51R protein's key role in facilitating viral replication, with potential implications for viral infection prevention and autoimmune disease intervention.
|
Prodrugs & Nanoparticles: How NanoScrips is Developing Therapies with Enhanced Safety and Efficacy
|
NanoScrips is a pharmaceutical company developing prodrugs and self-forming nanoparticles for multiple indications. The Carrollton-based company looks to succeed by selecting molecules with broader therapeutic applicability and known safety and efficacy profiles.
The current NanoScrips pipeline includes candidates for glaucoma, retinal neurodegeneration, radiation sensitization, NASH, Ulcerative Colitis, Epilepsy and Alzheimer's Disease. The company currently has an NIH grant for efficacy studies in retinal disorders.
|
FUNDING & MENTORSHIP OPPORTUNITIES
|
TechFW Brings North Texas into Space Alliance
as State Looks to Innovate the Final Frontier
|
TechFW and the Bay Area Houston Economic Partnership have issued a call for startups and companies to engage with the Space Alliance Technology Outreach Program (SATOP).
The SATOP is a state-funded Texas program administered by the Bay Area Houston Economic Partnership that provides free technical assistance to small businesses, startups, and entrepreneurs located in Texas. SATOP offers technical assistance through two programs:
- The 40 Hour Technical Assistance Program
- The Texas A&M Capstone Design Program
A consortium of Space Alliance Partners is the driving force behind the Space Alliance Technology Outreach Program (SATOP). Aerospace companies, universities, colleges, and the NASA Johnson Space Center have committed to provide free labor hours to assist small business owners in solving technical challenges.
|
Startup Prize Focus on Health Competition
Means Opportunity for Innovators
Application closes on April 19, 2024
|
Startup Prize: Focus on Health is a national entrepreneurial competition for early stage health-focused startups. We connect entrepreneurs with mentors, resources and investors at zero cost and zero equity to the founder for a chance to battle test their concepts and walk away with $10,000 in non-dilutive funding and other potential investment.
|
The Hill Prizes
Recognizing Life Science Innovators & High-Impact Research
Applications open May 1, 2024
|
The Hill Prizes, generously funded by Lyda Hill Philanthropies, aim to accelerate groundbreaking research ideas with high potential for real-world impact. These prizes celebrate the achievements of top innovators and researchers in Texas, spanning six categories: Medicine, Public Health, Engineering, Biological Sciences, Physical Sciences, and Technology. Each recipient of the prize will be awarded $500,000 in funding to further their work and drive innovation.
|
Unlocking Biotech: For the Non-Scientist
|
What role do the FDA and NIH play in drug discovery?
|
Join Biotech Primer and BioNTX for the BioBasics 101 class, which explores the basic principles and scope of Life Sciences. This course is designed for the NonScientist and delves into genetic engineering, biomanufacturing, and applying the fundamental biology principles used everyday in our industry
|
Upcoming Events & Opportunities
|
2024 Biofest Invest
Join BioMedSA to connect with potential investors from across the nation and Texas bioscience companies seeking investment funding and hear best practices and valuable advice from experts.
April 17, 2024 | San Antonio, TX
|
Where IS Healthcare Going? Conference
Join Healthcare Think Tank to learn where healthcare is going in two panel discussions – from entrepreneurs growing business both nationally and globally, to hearing about humanitarian efforts that are serving needs around the world.
April 18, 2024 | San Antonio, TX
|
Navigating Investments in Emerging Biotech/Pharma: Insights from Investors' Viewpoint
Join HBA to learn how investors evaluate potential investments, what they look for in promising startups, and how to position your company for success in fundraising endeavors.
April 18, 2024 | Dallas, TX
|
Future of Healthcare Summit
Join DFW Kellogg Alumni Network to discover the intersection of health tech, science, and equity, forging new economic strategies in healthcare innovation.
April 19, 2024 | Dallas, TX
|
UTA Research and Innovation Expo 2024
Join UTA to discover the ingenuity and creativity of students, faculty, and staff firsthand.
April 22, 2024 | Arlington, TX
|
Navigating the Federal R&D Funding Environment
Join BioNTX for a webinar as our speakers delve into guiding organizations through the intricacies of funding agencies and crafting a funding pathway aligned with their development stage.
April 24, 2024 | Zoom
|
See You at the 2024 BIO International Convention in June!
|
Join BioNTX and BIO to be apart of the world's largest international event for biotechnology, representing the full ecosystem of innovation and industry with over 20,000 leaders and professionals from across the globe.
|
The iC³ Life Science Summit: 10 Years of Innovation
October 3, 2024 - October 4, 2024
|
This year's 10th annual BioNTX iC³ Life Science Summit will provide dynamic platform and a gorgeous setting for the North Texas bioscience community to share insightful discussion, cutting-edge research, and emerging technologies set to revolutionize the future of healthcare and biomedicine. With a new, international focus; the 2024 iC³ Life Science Summit is proud to welcome the global life science community to North Texas.
|
Renew Your Membership in 2024
Our members are the Foundation of our work and the driving force behind industry growth in North Texas. BioNTX provides members with opportunities to connect and collaborate to gain business insights, thought leadership, access vital resources, share innovations, and increase market visibility.
|
|
